<DOC>
	<DOCNO>NCT02280720</DOCNO>
	<brief_summary>The purpose study compare vascular healing stented segment deployment titanium-nitride-oxide coat cobalt-chromium Optimax™-stent stent Promus-Element™ everolimus-eluting stent patient acute coronary syndrome require percutaneous coronary intervention . 1 . Comparison OCT CFR find titanium-nitride-oxide coated cobalt-chromium Optimax™-stent Promus-Element™ everolimus-eluting stent two month index procedure . 2 . Comparison intravascular coronary flow reserve measurement non-invasive transthoracic echocardiography-derived coronary flow reserve measurement . 3 . Comparison epicardial vasodilation coronary microcirculatory vasodilation</brief_summary>
	<brief_title>Vascular Healing After Deployment Titanium-nitride-oxide-coated OPTIMAX™ Stent PROMUS-ELEMENT™ Everolimus-Eluting Stent</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 80 year 2 . STEMI NSTEMI ( assume investigator type 1 myocardial infarction , accord universal definition MI ; EHJ 2007 ; 28 ( 20 ) :252538 ) ; unstable angina ( clinical symptom chest pain , ecg suggestive reversible ischemia ) 3 . Patient willing comply specify followup evaluation 4 . Patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Medical Ethics committee Institutional Review Board 5 . Single de novo nonstented restenosis lesion 6 . Patients twovessel disease may undergo successful treatment nontarget vessel approve device include index procedure must prior index target vessel treatment 7 . Target lesion ( maximum 20 mm length visual estimation ) cover single stent maximum 23mm length 8 . Reference vessel diameter must &gt; 2.5mm &lt; 4.0mm visual estimate . 9 . The vessel diameter measure predilation procedure intracoronary nitroglycerin vasospasm suspect 10 . Target lesion &gt; 50 % &lt; 100 % stenosed visual estimate 1 . Preexisting diagnosis diabetes irrespective type 2 . Impaired renal function ( serum creatinine &gt; 177micromol/l ) dialysis 3 . Platelet count &lt; 10 e5 cells/mm3 4 . Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulation therapy contraindicate 5 . Patient receive organ transplant wait list organ transplant 6 . Patient known hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/prasugrel , stainless steel alloy , contrast agent adequately premedicated 7 . Patient present cardiogenic shock 8 . Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study 9 . Currently participate another intestigational drug device study 10 . Unprotected leave main disease 11 . Ostial target lesion 12 . Chronic total occlusion 13 . Calcified target lesion adequately predilated 14 . Target lesion excessive tortuosity unsuitable stent delivery deployment 15 . Target lesion involve bifurcation side branch large 2.0mm diameter 16 . A &gt; 30 % stenosis proximal distal target lesion cover stent 17 . Diffuse distal disease 18 . Prior stent target vessel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>titanium-nitride-oxide-coated stent</keyword>
	<keyword>everolimus-eluting stent</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>strut coverage</keyword>
</DOC>